For the first time, dermatologists have a formal, evidence-based roadmap for managing severe alopecia areata (AA). A Delphi consensus statement published in JAMA Dermatology — developed in partnership with the National Alopecia Areata Foundation and the American Hair Research Society — names oral JAK inhibitors as the primary first-line treatment for adults with severe AA (defined as ≥50% scalp hair loss, or moderate/mild loss with additional complicating factors).

The panel of ~30 expert dermatologists recommends maintaining the same JAK inhibitor at the same dose for a full 6 months before making any changes. If response is inadequate, clinicians can increase the dose, switch to a different JAK inhibitor, or layer in adjunctive therapies like minoxidil, corticosteroids, or topical prostaglandins. Dupilumab was flagged as an alternative for patients with atopic conditions. The panel found insufficient evidence to support methotrexate, cyclosporine, hydroxychloroquine, or UV phototherapy for severe AA.

Key Takeaways:

• Three FDA-approved oral JAK inhibitors are preferred: baricitinib (Olumiant), ritlecitinib (Litfulo), and deuruxolitinib (Leqselvi)
• Continuous, long-term, uninterrupted treatment is essential for sustained response
• Recommendations apply only to adults with severe disease — not children, pregnant patients, or those with mild-to-moderate AA
• The consensus statement may help clinicians secure insurance reimbursement for JAK inhibitors

Why it matters: This is the first standardized U.S. treatment framework for severe AA, a condition that went from zero FDA-approved therapies to three JAK inhibitors in just a few years. Beyond clinical guidance, the published consensus gives clinicians a citable document to push back against insurance denials — a meaningful step forward for patients who need access to these effective but costly therapies.